Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: A randomized controlled trial

Figures & data

Figure 1.  Derivation of the study population.

Table I.  Baseline patient demographic and clinical and microscopic characteristics (95% confidence intervals) by treatment groups: pivmecillinam (n = 86) and sulfamethizole (n = 81).

Characteristics	Pivmecillinam treated	Sulfamethizole treated
Age, mean (range)	32 (18–64)	34 (17–61)
Symptoms:
Pollakisuria	89.3% (80.6; 95.0)	90% (81.4; 95.6)
Dysuria	81.2% (71.2; 88.8)	87% (78.5; 93.9)
Intensity of symptoms:
Moderate to severe pollakisuria	69.1% ( 57.9; 78.9)	65% (53.0; 75.0)
Moderate to severe dysuria	57.3% (45.9; 68.1)	54.4% (42.8; 65.7)
Duration of symptoms>3 days:
Pollakisuria	28.6% (19.2; 39.5)	35.8% (25.4; 47.2)
Dysuria	22.3% (14.0; 32.7)	29.6% (19.9; 49.8)
No. of bacteria per field of vision:
1–10	48.8% (37.9; 59.9)	45.0% (33.8; 56.5)
≥10	51.1% (40.1; 62.1)	55.0% (43.5; 66.2)
No. of leucocytes per field of vision:
1–10	81.4% (71.5; 90.0)	80.0% (69.6; 88.1)
≥10	18.6% (11.0; 28,4)	20.0% (11.9; 30.4)

Figure 2.  Percentage of patients with persistent dysuria and pollakisuria after treatment with sulfamethizole or pivmecillinam for uncomplicated urinary tract infection.

Table II.  Clinical and microbiological outcomes at follow-up visit 7–10 days after start of treatment.

	Pivmecillinam	Sulfamethizole	Difference (95% CI)
Clinical outcomes:
Clinical cure (no persistent urinary symptoms)
UTI, all infections (n = 167)	95.4%	92.6%	2.8% (−4.5%; 10.0%)
UTI caused by E. coli (n = 109)	96.4%	96.3%	0.1% (−7.0%; 7.1%)
UTI caused by sulfa resistant E. coli (n = 36)	95.5%	92.9%	2.6% (−13.5%; 18.6%)
UTI caused by sulfa susceptible E. coli (n = 73)	97.0%	97.5%	−0.5% (−8.1%; 7.1%)
UTI not caused by E. coli (n = 25)	93.3%	90.0%	3.3% (−19.16%; 25.8%)
UTI culture negative (n = 33)	93.8%	82.4%	11.4% (−10.2%; 33.1%)
Bacteriological outcomes:
Microbiological cure (< 10^3 CFU per ml)
UVI caused by all bacteria (n = 123)	68.8%	77.9%	−9.2% (−24.7%; 6.3%)
UVI caused by E. coli (n = 101)	72.6%	80.0%	−7.5% (−24.0%; 9.1%)
UTI caused by sulfa resistant E. coli (n = 34)	65.0%	85.7%	−20.7% (−48.5%; 7.1%)
UTI caused by sulfa susceptible E. coli (n = 67)	77.4%	77.8%	−0.3% (−20.4%; 19.7%)
UVI not caused by E. coli (n = 22)	53.8%	66.7%	−12.8% (−53.8%; 28.2%)